Infinity Pharmaceuticals, Inc. (INFIQ) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Infinity Pharmaceuticals, Inc. (INFIQ) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Die Aktie erzielt 62/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 15. März 2026Infinity Pharmaceuticals, Inc. (INFIQ) Gesundheitswesen & Pipeline-Uebersicht
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that was focused on developing novel cancer medicines, including eganelisib (IPI-549). The company filed for Chapter 11 bankruptcy in September 2023 and is currently undergoing liquidation, impacting its future prospects and operations within the biotechnology sector.
Investmentthese
Infinity Pharmaceuticals' Chapter 11 liquidation significantly alters its investment profile. The company's prior focus on eganelisib (IPI-549) and strategic alliances with companies like Verastem and Bristol Myers Squibb are now secondary to the bankruptcy proceedings. Key value drivers related to clinical trial outcomes and potential drug approvals are now defunct. Potential catalysts related to clinical data releases or partnership expansions are no longer relevant. The primary risk factor is the uncertainty surrounding the liquidation process and potential recovery for stakeholders. Investors should carefully consider the implications of the Chapter 11 liquidation before making any decisions regarding INFIQ.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization is $0.00B, reflecting the company's distressed financial state.
- Free cash flow is negative ($-0.00B), indicating the company's inability to generate positive cash flow from operations.
- Beta is 9.38, suggesting very high volatility compared to the overall market.
- No dividend is paid, reflecting the company's financial constraints.
- Chapter 11 liquidation approved on March 7, 2024, marking a significant turning point for the company.
Wettbewerber & Vergleichsunternehmen
Staerken
- Historically, a focus on immuno-oncology and targeted therapies.
- Strategic alliances with established pharmaceutical companies.
- Experienced management team (prior to bankruptcy).
Schwaechen
- Chapter 11 bankruptcy and liquidation.
- Lack of revenue-generating products.
- High cash burn rate.
Katalysatoren
- Upcoming: Not applicable due to liquidation.
- Ongoing: Chapter 11 liquidation proceedings.
Risiken
- Potential: Limited or no recovery for shareholders in the liquidation process.
- Ongoing: Uncertainty surrounding the timeline and outcome of the bankruptcy proceedings.
- Potential: Delisting from the OTC market.
- Potential: Legal challenges or disputes related to the liquidation.
- Ongoing: High volatility and speculative trading activity.
Wachstumschancen
- Growth opportunity 1: Not applicable. Given the Chapter 11 liquidation, Infinity Pharmaceuticals no longer has viable growth opportunities related to its previous clinical programs or strategic alliances. The company's assets are being liquidated, and its operations are ceasing.
- Growth opportunity 2: Not applicable. There are no growth opportunities for Infinity Pharmaceuticals due to the Chapter 11 liquidation.
- Growth opportunity 3: Not applicable. The company's bankruptcy eliminates any potential for future growth.
- Growth opportunity 4: Not applicable. Infinity Pharmaceuticals is in liquidation, so there are no growth opportunities.
- Growth opportunity 5: Not applicable. The company's situation precludes any growth prospects.
Chancen
- Not applicable due to liquidation.
Risiken
- Uncertainty surrounding the liquidation process.
- Potential for limited recovery for stakeholders.
- Loss of intellectual property and assets.
Wettbewerbsvorteile
- Historically, intellectual property rights and patents related to its drug candidates provided a potential moat.
- Strategic alliances with larger pharmaceutical companies offered a competitive advantage.
- The company's current moat is non-existent due to the Chapter 11 liquidation.
Ueber INFIQ
Founded in 1995 and headquartered in Cambridge, Massachusetts, Infinity Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company dedicated to discovering, developing, and delivering novel cancer treatments. The company's primary focus was on immuno-oncology product candidates, with its lead product candidate being eganelisib (IPI-549), an orally administered inhibitor of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Eganelisib was in Phase 2 clinical trials for metastatic triple-negative breast cancer and urothelial cancer, as well as Phase 1/1b trials for solid tumors. Infinity Pharmaceuticals pursued strategic alliances to expand its research and development capabilities. These included collaborations with Intellikine, Inc. (targeting PI3K delta and gamma isoforms), Verastem, Inc. (duvelisib), PellePharm, Inc. (IPI-926 hedgehog inhibitor program), F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. These partnerships aimed to accelerate the development and commercialization of innovative cancer therapies. However, on September 29, 2023, Infinity Pharmaceuticals and its affiliate filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on March 7, 2024, signaling a significant shift in the company's operational status.
Was das Unternehmen tut
- Focused on developing novel medicines for cancer treatment.
- Developed eganelisib (IPI-549), an immuno-oncology product candidate.
- Conducted Phase 2 clinical trials for metastatic triple negative breast cancer and urothelial cancer.
- Conducted Phase 1/1b clinical trials for solid tumors.
- Formed strategic alliances with Intellikine, Inc., Verastem, Inc., and PellePharm, Inc.
- Collaborated with F. Hoffmann-La Roche Ltd. and Bristol Myers Squibb Company.
- Filed for Chapter 11 bankruptcy in September 2023.
- Undergoing Chapter 11 liquidation as of March 2024.
Geschaeftsmodell
- Historically, Infinity Pharmaceuticals focused on developing and out-licensing or commercializing novel cancer therapies.
- The company relied on strategic alliances and collaborations to fund research and development.
- The company's business model is now centered on the liquidation of its assets to satisfy creditors.
Branchenkontext
Infinity Pharmaceuticals operated within the competitive biotechnology industry, characterized by high research and development costs, lengthy clinical trial processes, and regulatory hurdles. The industry is driven by innovation and the development of novel therapies for unmet medical needs. Companies like Infinity Pharmaceuticals often rely on strategic alliances and partnerships to share costs and accelerate drug development. However, the company's Chapter 11 liquidation reflects the inherent risks and challenges in the biotechnology sector, including clinical trial failures, funding constraints, and market competition.
Wichtige Kunden
- Historically, potential customers included patients with cancer and healthcare providers.
- Pharmaceutical companies were also customers through licensing and collaboration agreements.
- Currently, the company's primary customers are creditors and stakeholders involved in the bankruptcy proceedings.
Finanzdaten
Chart & Info
Infinity Pharmaceuticals, Inc. (INFIQ) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer INFIQ verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer INFIQ.
Kursziele
Wall-Street-Kurszielanalyse fuer INFIQ.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von INFIQ auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Wettbewerber & Vergleichsunternehmen
INFIQ OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Infinity Pharmaceuticals, Inc. does not meet the minimum financial standards or reporting requirements of the higher OTC tiers like OTCQX or OTCQB, or major exchanges like NYSE or NASDAQ. Companies in this tier may be distressed, bankrupt, or have limited information available to investors. Trading on the OTC Other tier carries significantly higher risks compared to listed exchanges due to less stringent regulations and oversight.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited or no financial disclosure.
- High risk of fraud or manipulation.
- Potential for delisting and complete loss of investment.
- Bankruptcy and liquidation proceedings.
- Extreme price volatility.
- Verify the company's legal status and bankruptcy filings.
- Assess the potential recovery for shareholders in the liquidation process.
- Review any available financial statements and disclosures.
- Understand the risks associated with OTC Other trading.
- Consult with a financial advisor.
- Determine the current share price and trading volume.
- Research the company's history and management team (prior to bankruptcy).
- Historically, the company had strategic alliances with reputable pharmaceutical companies.
- Prior to bankruptcy, the company had a focus on developing cancer therapies.
- The company was founded in 1995, indicating a long operating history (prior to bankruptcy).
Was Anleger ueber Infinity Pharmaceuticals, Inc. (INFIQ) wissen wollen
What are the key factors to evaluate for INFIQ?
Infinity Pharmaceuticals, Inc. (INFIQ) currently holds an AI score of 62/100, indicating moderate score. Key strength: Historically, a focus on immuno-oncology and targeted therapies.. Primary risk to monitor: Potential: Limited or no recovery for shareholders in the liquidation process.. This is not financial advice.
How frequently does INFIQ data refresh on this page?
INFIQ prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven INFIQ's recent stock price performance?
Recent price movement in Infinity Pharmaceuticals, Inc. (INFIQ) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Historically, a focus on immuno-oncology and targeted therapies.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider INFIQ overvalued or undervalued right now?
Determining whether Infinity Pharmaceuticals, Inc. (INFIQ) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying INFIQ?
Before investing in Infinity Pharmaceuticals, Inc. (INFIQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding INFIQ to a portfolio?
Potential reasons to consider Infinity Pharmaceuticals, Inc. (INFIQ) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Historically, a focus on immuno-oncology and targeted therapies.. Additionally: Strategic alliances with established pharmaceutical companies.. The AI-driven MoonshotScore of 62/100 reflects solid quantitative fundamentals. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of INFIQ?
Yes, most major brokerages offer fractional shares of Infinity Pharmaceuticals, Inc. (INFIQ) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track INFIQ's earnings and financial reports?
Infinity Pharmaceuticals, Inc. (INFIQ) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for INFIQ earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and news reports regarding Infinity Pharmaceuticals' Chapter 11 bankruptcy and liquidation.
- The company's financial situation is subject to change during the bankruptcy proceedings.
- This analysis is not investment advice and should not be construed as a recommendation to buy or sell INFIQ stock.